The Medicines (Products Other Than Veterinary Drugs) (General Sale List) Amendment Order 1994

Type Statutory-Instrument
Publication 1994-09-07
State In force
Department Queen's Printer of Acts of Parliament
PDF Download
articles 3
Reform history JSON API

Made: 7th September 1994

Coming into force: 12th October 1994

The Secretaries of State concerned with health in England, in Wales and in Scotland respectively and the Department of Health and Social Services for Northern Ireland, acting jointly in exercise of powers conferred upon them by sections 51 and 129(4) of the Medicines Act 1968[^f00001] or, as the case may be, those conferred by those provisions and now vested in them[^f00002], and of all other powers enabling them in that behalf, after consulting such organisations as appear to them to be representative of interests likely to be substantially affected by this Order[^f00003] and after consulting and taking into account the advice of the Medicines Commission pursuant to section 129(7) of that Act, hereby make the following Order:

Citation, commencement and interpretation

1

Amendment of article 1(2) of the principal Order

2

In article 1(2) of the principal Order (interpretation), after the definition of “dosage unit” there is inserted the following definition—

  • “effervescent”, in relation to a tablet, means containing not less than 75 per cent., by weight of the tablet, of ingredients included wholly or mainly for the purpose of releasing carbon dioxide when the tablet is dissolved or dispersed in water;

Amendment of Schedule 1 to the principal Order

3

(2) 15.8 per cent. (Fe SO4 7H2O)

, and in column 3 the entries

(1) Internal: except for use as cyanide antidote (2) Internal: for use as cyanide antidote only

and for the entry in column 4 there is substituted the entry

(1) Equivalent to 24 mg elemental Iron (MD)

SCHEDULE 1 — ENTRIES INSERTED IN TABLE A OF SCHEDULE 1 TO THE PRINCIPAL ORDER (INTERNAL OR EXTERNAL USE)

Column 1 Column 2 Column 3 Column 4
Substance Maximum strength Use, pharmaceutical form or route of administration Maximum dose and maximum daily dose
Acerola
Agnus castus (Chaste Tree)
Air
Alexitol Sodium
Alpha Tocopheryl Acid Succinate
Aluminium Carbonate (Basic)
Aluminium Oxide
Aminoacetic Acid (Glycine)
Aminobenzoic Acid 1 Internal 2 External (1) 30mg (MDD)
Ammonium Acetate Solution Strong
Amyloglycosidase Concentrate
Anethole
Aniseed (Anise)
Arrowroot
Balm of Gilead
Bayberry
Betacarotene 6 mg (MDD)
Bismuth Aluminate 6 mg (MD), calculated as Bismuth Oxide
Black Catechu
Black Haw
Blackberry
Black Currant
Bladderwrack (Fucus)
Blue Cohosh (Caulophyllum) 265 mg (MD)
Boneset (Eupatorium perfoliatum)
Buckthorn
Butternut (White Walnut)
Calamus (Sweet Flag)
Calcium Chloride
Calcium Heptagluconate
Calcium Phosphate
Calumba
Capsicum Oleoresin BPC 1923
Capsicum Oleoresin BPC 1973 (1) Internal (1) 1.2mg (MD)
(1) 1.8mg (MDD)
(2) 2.5 per cent. (2) External
Caraway Oil
Centaury
Chickweed
Chlorophenols 1 1 mg 2 0.6 per cent. 1 Internal 2 External
Cinnamic Acid (1) 500 mcg 1 Internal: pastilles, lozenges, throat tablets 2 External
Clove
Clover (Red Clover)
Cobalt Sulphate Equivalent to 0.25 mg elemental Cobalt (MDD)
Coriander
Dexpanthenol (Panthenol, Pantothenol)
Docosahexaenoic Acid (DHA)
Domiphen Bromide
Eicosapentaenoic Acid (EPA)
Euphorbia hirta (Euphorbia pilulifera, Pill-Bearing Spurge)
Fast Green FCF
Fennel Oil
Fenugreek
Ferric Chloride Equivalent to 24 mg elemental iron (MD)
Fibre, Vegetable
Fig
Fir Oil, Siberian
Frangulin
Fringe Tree
Fumitory 160 mg (MD)
Ginseng
Glutamic Acid Hydrochloride
Glycerophosphoric Acid
Gravel Root (Eupatorium purpureum)
Hamamelis
Heartsease
Hemlock Spruce (Pine Canadian) 400 mg (MD)
Horseradish
Hydrangea
Iceland Moss
Inositol
Iodophenol 1 0.2 mg 2 0.08 per cent. 1 Internal: pastilles, lozenges, throat tablets 2 External
Kaolin Heavy
Kava 625 mg (MD)
Kelp
Lady’s Mantle
Lemon
Lignocaine 1 0.6 per cent. 2 0.6 per cent. 1 Internal: teething gel 2 External, except local ophthalmic use
Lignocaine Hydrochloride 1 0.7 per cent. 2 0.7 per cent. 1 Internal: teething gel 2 External, except local ophthalmic use
Liquorice Extract Deglycyrrhizinised
Lucerne (Alfalfa)
Lungwort
Magnesium Stearate
Maize
Malted Milk
Maltose
Manganese Glycerophosphate Equivalent to 1 mg elemental Manganese (MDD)
Marshmallow Root
Methionine, DL
Motherwort
Myrrh
Nutmeg
Oak Bark
Orange
Pantothenic Acid
Papain
Parsley
Pellitory
Pilewort
Pleurisy Root
Poke Root (Phytolacca) 1 Internal 2 External (1) 120 mg (MD)
Poplar (Aspen)
Potassium Acid Tartrate
Potassium Bicarbonate
Potassium Carbonate
Potassium Citrate
Potassium Molybdate Equivalent to 200 mcg elemental molybdenum (MDD)
Psyllium
Queen’s Delight 320 mg (MD)
Raspberry
Rosemary
Rubellin
Rutin
Saw Palmetto
Shepherd’s Purse
Skunk Cabbage (Symplocarpus)
Sodium Sulphate
Sodium Acid Phosphate
Sodium Glycerophosphate
Sodium Phosphate
Squaw Vine
Squill, Indian
Stone Root
Tilia (Lime Flowers)
Unicorn Root False
Uva Ursi (Bearberry)
Wahoo (Euonymus atropurpureus)
Watercress
Wheat
Wild Indigo
Wood Betony
Xanthan Gum
Yellow Dock
Zinc Gluconate Equivalent to 5 mg elemental zinc (MDD)

SCHEDULE 2 — ENTRIES INSERTED IN TABLE B OF SCHEDULE 1 TO THE PRINCIPAL ORDER (EXTERNAL USE ONLY)

Column 1 Column 2 Column 3
Substance Maximum Strength Use, Pharmaceutical Form or Route of Administration
Aldioxa (Aluminium Dihydroxyallantoinate)
Allantoin
Aminacrine Hydrochloride
Arnica
Bay Oil
Borax (Sodium Borate) 1 5.0 per cent. 2 0.7 per cent. 1 All preparations except ophthalmic lotions 2 Ophthalmic lotions
Boric Acid 2.5 per cent.
Bryony, Black
Burgundy Pitch
Calcium Undecylenate
Calendula (Marigold)
Cedar Wood Oil
Colophony
Comfrey Root
Crotamiton
Dichlorotetrafluroethane
Emulsifying Wax
European Birch
Geranium Oil
Guaiacol
Halquinol 0.6 per cent.
Heparin
Hexetidine 0.1 per cent.
Hexyl Nicotinate 2.0 per cent.
Horse-chestnut (Aesculus)
Hypericum (St. John’s Wort)
Hypophosphorous Acid
Isopentane
Labrador Tea
Lactic Acid
Light Liquid Paraffin
Linseed Oil
Mastic
Melaleuca Oil
Methoxymethane
Mexenone
Microcrystalline Wax
Oleyl Alcohol
Paeony (Peony)
Polyethoxyethanol
Potassium Chloride
Potassium Hydroxide
Potassium Thiocyanate
Propylene Glycol
Pyrethrum (Chrysanthemum)
Rue 0.1 per cent.
Shark Liver Oil 1 3.0 g 1 Suppositories 2 All preparations for external use except suppositories
Sodium Acid Pyrophosphate
Sodium Pyrophosphate
Southern Wood
Talc
Tar
Terebene (Terepene)
Thurfyl Salicylate
Titanium Peroxide
Titanium Salicylate
Wool Alcohols, Acetylated
Zinc Oleate

Signed

Signed by authority of the Secretary of State for Health

Tom Sackville — Parliamentary Under Secretary of State, — Department of Health — 16th September 1994

John Redwood — Secretary of State for Wales — 6th September 1994

Allan Stewart — Parliamentary Under Secretary of State, The Scottish Office — 6th September 1994

Sealed with the Official Seal of the Department of Health and Social Services for Northern Ireland on

F. A. Elliott — Permanent Secretary — 7th September 1994.

Explanatory note

(This note is not part of the Order)

This Order further amends the Medicines (Products Other Than Veterinary Drugs) (General Sale List) Order 1984 (“the principal Order”) which specifies classes of medicinal products which can with reasonable safety be sold or supplied otherwise than by or under the supervision of a pharmacist (the general sale list).

Article 2 inserts a definition of “effervescent” in the principal Order.

Article 3 amends Schedule 1 to the principal Order (medicinal products, other than products the subject of a product licence of right, on general sale). Article 3(2) inserts in Table A (internal or external use) of that Schedule the entries specified in Schedule 1 to this Order and amends other entries in Table A as described in paragraph (2)(d) to (l).

Article 3 (3) inserts in Table B (external use only) of Schedule 1 to the principal Order the entries specified in Schedule 2 to this Order, omits from Table B the entries in respect of Hamamelis, Siberian Fir Oil, Lignocaine and Lignocaine Hydrochloride (which now appear, amended, in Table A of that Schedule) and amends the entry in respect of Povidone-Iodine.

Footnotes

[^f00001]: 1968 c. 67. The expressions “the appropriate Ministers” and “the Health Ministers” are defined in section 1 of that Act as amended by S.I. 1969/388, Schedule 1.

[^f00002]: In the case of the Secretaries of State concerned with health in England and in Wales by virtue of article 2(2) of, and Schedule 1 to, the Transfer of Functions (Wales) Order 1969 (S.I. 1969/388); in the case of the Department of Health and Social Services for Northern Ireland by virtue of section 40 of, and Schedule 5 to, the Northern Ireland Constitution Act 1973 (c. 36) and section 1(3) of, and paragraph 2(1)(b) of Schedule 1 to, the Northern Ireland Act 1974 (c. 28).

[^f00003]: See section 129(6) of the Medicines Act 1968.

[^f00004]: S.I. 1984/769, amended by S.I. 1985/1540, 1987/910, 1989/969, 1990/1129 and 1992/1535.

Reading this document does not replace reading the official text published on legislation.gov.uk. Contains public sector information licensed under the Open Government Licence v3.0. We assume no responsibility for any inaccuracies arising from the conversion of the original CLML XML to this format.

This text is published under legislation.gov.uk's own terms of reuse, not a Legalize or public-domain licence. legislation.gov.uk
Open Government Licence v3.0 (attribution required)
© Crown and database right. Derived from content available under the Open Government Licence v3.0 from legislation.gov.uk.